Independent comparison · May 2026
Quick answer
Tirzepatide (the active ingredient in Mounjaro and Zepbound) delivers more weight loss on average than semaglutide (the active ingredient in Ozempic and Wegovy) — roughly 5 percentage points more body-weight reduction in clinical trials. Semaglutide costs less, has a longer real-world track record, and is the more common starting molecule. The right choice depends on goals, tolerance, and budget.
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Avg trial weight loss | 14.9% at 68 weeks | 15–22% at 72 weeks |
| Compounded price (cheapest legit) | From $99/month | From $146/month |
| Dosing | Weekly | Weekly |
| Oral version available | Yes (Rybelsus) | No |
| Years on US market | Since 2017 (Ozempic) | Since 2022 (Mounjaro) |
Semaglutide activates one receptor — GLP-1. Tirzepatide activates two — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual activation produces stronger appetite suppression and improved insulin efficiency in trial conditions.
The trade-off: more potent action sometimes means more pronounced GI side effects during the initial titration window. Most patients adapt within 4–8 weeks but a meaningful minority find tirzepatide harder to start.
First-time GLP-1 users often start on semaglutide because the longer real-world track record means more predictable side-effect management and a cheaper price point. The 14.9% average weight loss is more than enough to hit most goals if taken to therapeutic dose.
Patients sensitive to GI side effects, those on a tighter monthly budget, and patients who want the option of an oral version (Rybelsus) often choose semaglutide first.
Patients with a higher BMI, those who plateaued on semaglutide, or those who simply want the strongest clinically-supported weight loss often start on or switch to tirzepatide. The 5-point-higher average response can be the difference between hitting a 15% goal and stopping at 10%.
Tirzepatide also tends to perform better on metabolic markers like A1C and triglycerides in patients with prediabetes or diabetes alongside obesity.
Independently rated providers that prescribe these medications, sorted by editorial score.
Comprehensive GLP-1 programs with board-certified physicians and lab monitoring
Excellent
Highest-converting GLP-1 provider — $16 EPC, personalized consultations, tailored prescriptions
Excellent
Fastest-growing GLP-1 provider — oral, sublingual, and injectable options with Affirm financing
Excellent
150K+ members with 5 medication forms — injections, oral drops, lozenges, tablets, and pills
Very Good
On average, tirzepatide produces about 5 percentage points more body-weight loss than semaglutide in clinical trials. Whether it is 'better' for an individual depends on tolerance, response, and cost. Many providers start patients on semaglutide and switch to tirzepatide if response is insufficient.
Yes, with a licensed provider's supervision. Switching requires a new intake and a fresh titration schedule starting at the lowest dose of the new drug.
Yes. Compounded semaglutide telehealth plans typically start at $99/month while compounded tirzepatide starts at $146/month at the cheapest legit providers.